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Abstract: Gastroesophageal reﬂ  ux disease (GERD) is a chronic, relapsing disease that can 
progress to major complications. Affected patients have poorer health-related quality of life 
than the general population. As GERD requires continued therapy to prevent relapse and 
complications, most patients with erosive esophagitis require long-term acid suppressive 
treatment. Thus GERD results in a signiﬁ  cant cost burden and poor health-related quality of 
life. The effective treatment of GERD provides symptom resolution and high rates of remission 
in erosive esophagitis, lowers the incidence of GERD complications, improves health-related 
quality of life, and reduces the cost of this disease. Proton pump inhibitors are accepted as the 
most effective initial and maintenance treatment for GERD. Oral pantoprazole is a safe, well 
tolerated and effective initial and maintenance treatment for patients with nonerosive GERD or 
erosive esophagitis. Oral pantoprazole has greater efﬁ  cacy than histamine H2-receptor antagonists 
and generally similar efﬁ  cacy to other proton pump inhibitors for the initial and maintenance 
treatment of GERD. In addition, oral pantoprazole has been shown to improve the quality of life 
of patients with GERD and is associated with high levels of patient satisfaction with therapy. 
GERD appears to be more common and more severe in the elderly, and pantoprazole has shown 
to be an effective treatment for this at-risk population.
Keywords: pantoprazole, proton pump inhibitor, erosive esophagitis, gastroesophageal reﬂ  ux 
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Introduction
Gastroesophageal reflux disease (GERD) is a chronic, relapsing disease that 
infrequently progresses (Sontag et al 2006) but is associated with a range of potentially 
serious esophageal complications (esophageal ulcer, esophageal stricture or obstruction, 
Barrett’s esophagus or esophageal cancer) and extra-esophageal diseases such as 
respiratory problems, chest pain, angina, and increased mortality (Ruigomez et al 2004). 
It is characterized by reﬂ  ux of the stomach contents into the esophagus, oropharynx, 
larynx, or airway and is associated with heartburn, acid regurgitation, and dyspepsia (Dent 
et al 1999; Farup et al 2001a; Shaker et al 2003; Orlando 2006). Other less common 
symptoms of GERD include cough, intermittent wheezing, vocal cord inﬂ  ammation, 
atypical chest pain, dysphagia, and hoarseness. Simply put, GERD has been deﬁ  ned as 
“a condition which develops when the reﬂ  ux of stomach contents causes troublesome 
symptoms and/or complications” (Vakil et al 2006).
Gastroesophageal reﬂ  ux disease is one of the most common chronic gastrointestinal 
disorders (Haag and Holtmann 2003). It has been reported that GERD affects an 
estimated 19 million individuals in the US (Sandler et al 2002), and it can affect 
up to one-third of adults (Haag and Holtmann 2003). These ﬁ  gures are likely to 
underestimate the true prevalence of GERD, since many patients self-medicate and 
do not seek medical advice or diagnosis (Fendrick 2001). Similarly, many patients are Therapeutics and Clinical Risk Management 2007:3(2) 232
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not aware that they have GERD (Hollenz et al 2002). Failure 
to seek professional medical treatment can lead physicians 
to under-diagnose and under-treat GERD, with consequent 
poor control of symptoms, lost productivity, reduced 
quality of life, and an increased incidence of complications 
in affected patients. Ultimately, this under-diagnosis and 
under-treatment result in increased long-term healthcare 
utilization and costs.
This article provides an overview of GERD and the issues 
that must be considered during the long-term management 
of the disease; literature concerning the long-term treatment 
of GERD with the proton pump inhibitor (PPI) pantoprazole 
is then reviewed.
Long-term management issues 
in GERD
In healthy individuals, reﬂ  ux of gastric contents occurs 
naturally without causing esophageal damage. However, 
in susceptible individuals, esophageal exposure to gastric 
contents causes either microscopic or macroscopic mucosal 
defects and the symptom of heartburn (Orlando 2006). The 
exact pathologic process by which this occurs is complex and 
yet to be fully characterized, but there are two requirements for 
heartburn, regardless of a diagnosis of erosive or nonerosive 
disease: these are high concentrations of acid within the 
esophageal lumen (reflux) and a damaged esophageal 
epithelium. When these situations co-exist, luminal acid 
enters the tissue where stimulation of nociceptors results 
in the symptom of heartburn (Orlando 2006). The major 
determinants of the severity of esophageal damage are the 
degree and duration of esophageal acid exposure in patients 
with impaired esophageal defenses (including increased 
frequency and duration of transient relaxations of the lower 
esophageal sphincter, impaired motility, decreased mucosal 
resistance, delayed gastric emptying, and presence of hiatus 
hernia) (Rai and Orlando 1998; Van Herwaarden et al 2000). 
In patients with nonerosive GERD, mucosal breaks are 
only apparent microscopically and are characterized by the 
presence of dilated intercellular spaces, whereas in patients 
with erosive esophagitis, breaks in the esophageal epithelium 
are visible on endoscopy. Nonerosive GERD can progress 
to erosive disease in susceptible patients (Orlando 2006) 
although initial severity of GERD is maintained in most 
patients (Vakil et al 2006). Erosive esophagitis is a chronic, 
recurring disease that can lead to further complications 
such as ulceration if long-term management is ineffective; 
secondary ﬁ  brosis and scarring can infrequently lead to 
esophageal stricture (Orlando 1999; Sontag et al 2006; 
Vakil et al 2006). A 20-year follow-up of 2306 patients who 
received symptom-driven antireﬂ  ux treatment indicated that 
only one patient with a normal baseline mucosa developed 
esophageal stricture requiring dilation (0.08%), but that 
18 patients with an erosive baseline mucosa were affected 
(1.9%). The overall incidence of stricture in patients with 
GERD was <1/1,000 per year (Sontag et al 2006).
With time, patients with GERD may develop 
histopathological changes such as Barrett’s esophagus 
(Spechler and Goyal 1986). GERD and Barrett’s esophagus 
are signiﬁ  cant risk factors for esophageal adenocarcinoma 
(Lassen et al 2006; Vakil et al 2006), the incidence of which 
has increased in Western industrialized nations over the last 
two decades (Bollschweiler et al 2001). In 2002, the incidence 
of esophageal adenocarcinoma was 26 per 100 000 person-years 
among patients with previously diagnosed erosive esophagitis 
(versus 2.79 per 100 000 person-years in the general 
population) in a Danish community (Lassen et al 2006). The 
risk of this life-threatening cancer is greatest in patients with 
more severe, frequent, and prolonged symptoms of GERD 
(Lagergren et al 1999). Severe GERD (GERD characterized 
by erosions, ulcers, and strictures) occurs more frequently in 
men, the elderly, and those of white ethnicity than in other 
populations (El-Serag and Sonnenberg 1997). Infection 
with Helicobacter pylori does not appear to contribute to 
the development of GERD (Csendes et al 1997; Labenz 
and Malfertheiner 1997; Raghunath et al 2003; Sharma and 
Vakil 2003).
Diagnosis
The differential diagnosis of GERD is often difﬁ  cult. The 
intensity and frequency of heartburn and other symptoms 
of GERD are poor predictors of the presence or severity 
of esophageal manifestations (Johansson et al 1986; Green 
1993; Fennerty et al 2002) meaning that symptom assessment 
alone is not a reliable method to assess the presence or 
severity of erosive disease (Dent et al 1999; Johnson and 
Fennerty 2004). However, since objective testing is not 
common in primary practice, it has been suggested that 
GERD is likely when heartburn occurs on two or more days 
a week, although less frequent symptoms do not preclude 
disease (Dent et al 1999).
Initiation of empiric therapy with acid suppressive 
therapy, usually a PPI, in patients with symptoms consistent 
with GERD is an efﬁ  cient and acceptable method to conﬁ  rm 
GERD; this method lacks speciﬁ  city (Numans et al 2004). Therapeutics and Clinical Risk Management 2007:3(2) 233
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If symptoms are relieved by therapy, a diagnosis of GERD 
can be assumed (DeVault and Castell 1999; Fass et al 
1999, 2000; Habermann et al 2002). GERD can also be 
diagnosed using 24-hour pH monitoring, but this test has 
limitations because there is no direct information as to the 
extent of esophageal damage (Arango et al 2000). Additional 
conﬁ  rmatory diagnostic tests include endoscopy, biopsy, 
barium radiography, examination of the throat and larynx, 
esophageal motility testing, emptying studies of the stomach, 
and esophageal acid perfusion. Of these tests, endoscopy is 
the only reliable method to diagnose erosive esophagitis and 
determine its severity (Tefera et al 1997).
Aims of treatment
The main aim of GERD treatment should be rapid and 
sustained achievement of comprehensive symptom resolution, 
because this is associated with marked improvement—often 
normalization—in health-related quality of life (Revicki et al 
1999). The other primary aims are to heal esophageal mucosal 
damage if it is present and to prevent relapse of erosive 
esophagitis in the hope that this will reduce the development 
of other serious complications.
Adequate treatment of GERD should either prevent 
repeated reﬂ  ux of gastric contents into the esophagus or reduce 
the damaging effect of gastric acid. As no pharmaceutical 
agent can fully correct the motor dysfunction responsible 
for acid reﬂ  ux into the esophagus, acid suppression remains 
the most effective way to relieve symptoms and to promote 
healing of esophagitis in patients with GERD (Orlando 
1997).
Treatment options
A number of pharmacological and surgical treatment 
options are available for patients with GERD. For most 
patients, initial acid suppressive therapy with a PPI is 
recommended. Once healing is achieved, the majority of 
patients with erosive esophagitis will require continued 
long-term (maintenance) acid suppressive treatment, 
usually with a lower dosage of their initial acid-
suppressive therapy. This is because GERD is a chronic, 
usually lifelong disease that often relapses once treatment 
is stopped. In fact, relapse rates of 81% to 90% have been 
reported in patients with healed erosive esophagitis 6 to 
12 months after drug therapy was withdrawn (Hetzel et al 
1988; Chiba 1997; Carlsson et al 1998) and it is generally 
accepted that symptoms will persist in most patients (Vakil 
et al 2006).
Pharmacological options
The main acid suppressive agents available for patients 
with GERD are antacids, H2-receptor antagonists, and PPIs. 
Antacids do not usually provide sufﬁ  cient acid suppression 
for patients with GERD. H2-receptor antagonists decrease 
gastric acid secretion by competitive and reversible blockade 
of histamine H2-receptors on the parietal cells of the gastric 
mucosa. H2-receptor antagonists are significantly more 
effective than antacids for suppressing acid secretion, but 
have a slower onset of action (Netzer et al 1998; Wyeth 
et al 1998). Use of H2-receptor antagonist is limited by drug 
tolerance, which can result in about a 50% reduction in 
efﬁ  cacy that cannot be reversed by dose increases (Nwokolo 
et al 1990; Kahrilas et al 1999). Over-the-counter preparations 
of low-dose H2-receptor antagonists (cimetidine, famotidine, 
nizatidine, and ranitidine) are also available. These are 
relatively safe, but are not effective in the vast majority of 
patients (Shaw et al 2001).
Proton pump inhibitors are widely recognized as the most 
effective agents for treating GERD. They are the mainstay of 
initial GERD management (DeVault and Castell 1999) and 
are the preferred agents for maintenance therapy in patients 
with healed erosive esophagitis (DeVault and Castell 1999; 
Crawley and Maclin Schmitt 2000). PPIs provide more rapid 
symptom control and better healing of erosive esophagitis 
than both H2-receptor antagonists and antacids (Chiba et al 
1997; Dent et al 1999; DeVault and Castell 1999; Caro et al 
2001; Donnellan et al 2004). 
Proton pump inhibitors block the ﬁ  nal step in the secretion 
of hydrochloric acid by binding to and inactivating H+/
K+ATPase in parietal cells of the gastric mucosa (Bell and 
Hunt 1992; Sachs 1997). PPIs thus produce a considerable but 
dose-dependent elevation of gastric pH (Dajani 2000). The 
prolonged hypochlorhydria seen with PPI therapy has raised 
safety concerns for patients receiving long-term therapy with 
these agents (possible enterochromafﬁ  n-like cell hyperplasia 
and gastric carcinoids, colorectal adenocarcinoma and 
polyps, and bacterial overgrowth as a result of achlorhydria). 
However, the magnitude of hypergastrinemia associated 
with PPI use is similar to that observed after vagotomy, 
and is 3-to 6-fold lower than that observed with pernicious 
anemia. Evidence to date indicates that any morphological 
changes in gastric endocrine cells are minimal, self-
limiting, nondysplastic and non-neoplastic, suggesting that 
hypergastrinemia observed during PPI therapy has little 
clinical signiﬁ  cance (Freston 1997). Thus, monitoring of 
serum gastrin levels and fundic enterochromafﬁ  n-like cells Therapeutics and Clinical Risk Management 2007:3(2) 234
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is of no clinical relevance even during long-term therapy 
with PPIs (Arnold 1994). PPIs are associated with a low 
rate of drug-drug reactions, other than those expected by the 
lowering of intragastric pH (Labenz et al 2003; Robinson and 
Horn 2003). Of the PPIs, omeprazole has the highest risk for 
hepatic-based interactions, and rabeprazole and pantoprazole 
appear to have the lowest risk (Robinson and Horn 2003). Of 
these lower risk agents, pantoprazole is the only PPI with a 
well characterized interaction proﬁ  le (Blume et al 2006).
Surgery
Although surgery (open, endoscopic, or laparoscopic) is 
an option for some patients with GERD, the outcomes of 
corrective procedures vary widely depending on the experience 
and skill of the surgeon (Watson et al 1996; Johnson 2003). 
Surgery is not an ideal option for the majority of patients, 
and many patients will continue to use acid reducing 
medications on a regular basis after undergoing surgery 
(Spechler et al 2001; Johnson 2003). In comparison with 
pharmacotherapy in the US, surgical antireﬂ  ux therapy (open 
Nissen fundoplication) produces no signiﬁ  cant differences in 
grade of esophagitis, frequency of treatment of esophageal 
stricture, and subsequent antireﬂ  ux operations, incidence 
of esophageal cancer, quality of life measures, and overall 
satisfaction with antireflux therapy when assessed more 
than 9 years after initiation of  therapy (Spechler et al 2001). 
Similarly, in Europe, PPI therapy demonstrates similar efﬁ  cacy 
to open antireﬂ  ux surgery in terms of prevalence of Barrett’s 
esophagus or strictures requiring dilatation, incidence of 
GERD-associated symptoms or quality of life at 3 years’ 
follow up (Lundell et al 2000), but after 5 years is associated 
with lower total medical costs (operation, endoscopy, visits 
to the outpatient clinic, and medication) for chronic GERD 
(Myrvold et al 2001). Laparoscopic fundoplication is not 
without complications: surgical complications such as gastric 
perforation or hernia can occur; medical therapy is required 
for control of heartburn in approximately one third of patients 
after this procedure; and new gastric symptoms are common 
after surgery (Vakil et al 2003).
Efﬁ  cacy, safety, and tolerability 
of pantoprazole
Efﬁ  cacy
Initial therapy
Oral pantoprazole is an effective treatment option for the 
initial treatment of nonerosive GERD or erosive esophagitis. 
It is most effective for healing erosive esophagitis when 
administered at a dose of 40 mg once daily (van Rensburg 
et al 1996; Richter and Bochenek 2000).
In patients with endoscopically conﬁ  rmed mild to severe 
erosive esophagitis, oral pantoprazole 20 mg/day or 40 
mg/day is more effective for healing of erosions and relief 
of GERD symptoms than the H2-receptor antagonists with 
which it has been compared (Cheer et al 2003; Bochenek et al 
2004) and generally has similar efﬁ  cacy to other PPIs on a mg 
per mg basis (Cheer et al 2003; Scholten et al 2003; Gillessen 
et al 2004; Achim et al 2005; Glatzel et al 2006). Oral 
pantoprazole 20 mg daily also provided clinical improvement 
in symptoms of erosive esophagitis in children aged 6 to 13 
years enrolled in a small uncontrolled trial (Madrazo-de la 
Garza et al 2003). These latter ﬁ  ndings are supported by the 
results of two recently completed studies. In these studies, oral 
pantoprazole at doses of 20 mg and 40 mg once daily for 8 
weeks rapidly reduced symptom scores in 53 children aged 5 
to 11 years with erosive or histological esophagitis (p < 0.001) 
(Tolia et al 2006) and in 136 adolescents aged 12 to 16 years 
with clinically diagnosed GERD (p < 0.001) (Tsou et al 
2006). Pantoprazole 10 mg daily also produced signiﬁ  cant 
improvement in symptoms, but was not as effective as the 
higher doses in children (Tolia et al 2006).
Maintenance therapy
Pantoprazole 20 mg or 40 mg daily as maintenance therapy 
prevents relapse of erosive esophagitis for 6 to 24 months 
in most patients with healed disease (Mossner et al 1997; 
Escourrou et al 1999; Van Rensburg et al 1999; Plein et al 
2000), regardless of patients’ initial disease severity (Metz 
and Bochenek 2003; Richter et al 2004). Pantoprazole 20 mg 
once daily has generally shown similar efﬁ  cacy for preventing 
endoscopic or symptomatic relapse to pantoprazole 40 mg 
once daily (Escourrou et al 1999; Plein et al 2000). In the 
larger of the two trials designed to statistically compare 
these pantoprazole regimens, daily doses of 20 mg and 40 
mg maintained 75% and 78% of patients, respectively, in 
endoscopic remission after 12 months, with Savary-Miller 
stage I disease accounting for about 50% of the endoscopic 
relapses (Plein et al 2000). Symptomatic remission rates 
after 12 months were also similar with each pantoprazole 
regimen: 77% with the 20 mg dose and 76% with the 40 mg 
dose. No correlation was seen between endoscopic relapse 
and perception of symptoms, or between the baseline severity 
of GERD and the maintenance dose of pantoprazole (Plein 
et al 2000). However, in two dose-ranging comparisons with 
ranitidine, patients receiving pantoprazole 40 mg daily were Therapeutics and Clinical Risk Management 2007:3(2) 235
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signiﬁ  cantly more likely to remain in remission than patients 
receiving pantoprazole 20 mg daily (p < 0.03 and p < 0.001) 
(Table 1) (Metz and Bochenek 2003; Richter et al 2004).
In comparisons with other active treatments, pantoprazole 
has demonstrated high remission rates. Pantoprazole 20 
mg or 40 mg is more effective than ranitidine 150 mg once 
or twice daily for maintaining healing of GERD after 12 
months of therapy (Table 1) (Adamek et al 2001; Metz 
and Bochenek 2003; Richter et al 2004). Patients receiving 
pantoprazole have signiﬁ  cantly higher endoscopic remission 
rates at 12 months (Table 1) and symptomatic control is 
also signiﬁ  cantly better, as measured by the proportion of 
symptom-free patients at 12 months (Table 1) (Adamek et al 
2001), the number of symptom-free days during the 12-month 
period (83% of days vs 58% of days, p < 0.001 [Richter 
et al 2004] and 78% vs 48%, p < 0.001 [Metz and Bochenek 
2003]) and the number of nights without heartburn (93% 
of nights vs 77% of nights, p = 0.001 [Richter et al 2004] 
and, p = 0.002 [Metz and Bochenek 2003]). In addition, 
pantoprazole maintains patients in remission for a longer 
period of time than does ranitidine (Metz and Bochenek 
2003). Pantoprazole is more effective than ranitidine in 
maintaining endoscopically conﬁ  rmed healing, regardless of 
initial disease severity or H. pylori status (Metz and Bochenek 
2003, Richter et al 2004).
Only a few studies have evaluated the efficacy of 
maintenance therapy with pantoprazole in comparison with 
other PPIs. The data available indicate that pantoprazole 20 
mg has similar efﬁ  cacy to omeprazole 20 mg for maintaining 
endoscopic and symptomatic remission in patients with 
healed erosive esophagitis (Lauritsen et al 2000). In 
comparisons with esomeprazole 20 mg daily, there are two 
studies showing conﬂ  icting results. Whereas the study by 
Labenz and colleagues (2005) showed esomeprazole 20 mg 
daily to be superior to pantoprazole 20 mg daily, the study 
by Goh and colleagues (2007) showed esomeprazole 20 mg 
Table 1 Randomized clinical trials comparing the efﬁ  cacy of maintenance therapy with pantoprazole versus other acid suppressing 
agents in patients with healed erosive esophagitisa
Reference  Treatment (No of patients)  Endoscopic   Symptomatic 
   remission    control 
    rate at study   at study end 
    end (% patients)  (% patients)
Comparisons with other proton pump inhibitors
Goh et al 2007   Pantoprazole 20 mg once daily (636)    84b
(double-blind, 6-month trial)  Esomeprazole 20 mg once daily (667)    85b 
Labenz et al 2005   Pantoprazole 20 mg once daily (1389)  77** 88.5*
(double-blind, 6-month trial)  Esomeprazole 20 mg once daily (1377)  88  92
Lauritsen et al 2000   Pantoprazole 20 mg once daily (211)  77  83
(double-blind, 12-month trial)  Pantoprazole 40 mg once daily (218)  83  87
  Omeprazole 20 mg once daily (210)  81  86
Comparisons with ranitidine
Adamek et al 2001   Pantoprazole 20 mg once daily(199)  66** 73%*
(double-blind, 12-month trial)  Ranitidine 150 mg once daily (104)  34  65%
Metz et al 2003   Pantoprazole 10 mg once daily (89)  40
(double-blind, 12-month trial)  Pantoprazole 20 mg once daily (93)  68
  Pantoprazole 40 mg once daily (94)  82
  Ranitidine 150 mg twice daily (95)  33†
Richter et al 2004   Pantoprazole 10 mg once daily (88)  46
(double-blind, 12-month trial)  Pantoprazole 20 mg once daily (88)  55*
  Pantoprazole 40 mg once daily (85)  78*
  Ranitidine 150 mg twice daily (88)  21
Note: aResults of intention-to-treat analyses; bEndoscopic plus symptomatic control; *p < 0.001; **p ≤ 0.0001 versus esomeprazole or ranitidine; †p < 0.001 versus all doses 
of pantoprazole.Therapeutics and Clinical Risk Management 2007:3(2) 236
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daily to be as effective as pantoprazole 20 mg daily in keeping 
patients in combined endoscopic and symptomatic remission 
(Table 1).
In the above trials the symptoms assessed were heartburn, 
dysphagia or pain on swallowing, and acid regurgitation. 
In some instances, additional gastric symptoms were also 
included (Plein et al 2000; Labenz et al 2005), but long-
term data regarding the efﬁ  cacy of pantoprazole for control 
of respiratory or laryngeal symptoms of GERD are not 
available. However, long-term high-dose PPI therapy is 
the ﬁ  rst-line approach to controlling these extraesophageal 
GERD symptoms (Halstead 2005).
Pantoprazole has also demonstrated efﬁ  cacy in difﬁ  cult-
to-treat patients. In 66 patients with aggressive, complicated 
GERD refractory to H2-receptor antagonists, but healed with 
oral pantoprazole, continued therapy with oral pantoprazole 
40 mg daily maintained remission in most patients at 24 
months (percentages were not reported) (Bardhan et al 
2001).
It is common for many patients with mild disease 
and infrequent symptom relapses to use a PPI only when 
symptoms demand. Patients with symptomatic or mild 
erosive GERD are therefore ideal candidates for on-demand 
or intermittent treatment (Bardhan 2003). On-demand 
treatment with oral pantoprazole 20 mg or 40 mg daily 
provided effective symptomatic control in 634 patients with 
endoscopically conﬁ  rmed Savary-Miller grade 0/I GERD and 
heartburn, with the mean perceived average daily symptom 
load of heartburn over a 6-month period reduced from 3.93 
with placebo to 2.71 with the 40 mg dose and 2.91 with the 20 
mg dose (p < 0.0001 for both pantoprazole doses vs placebo) 
(Scholten, Dekkers, et al 2005). The discontinuation rate due 
to insufﬁ  cient control of heartburn or unsatisfactory treatment 
(insufﬁ  cient control of heartburn or other gastrointestinal 
symptoms) was signiﬁ  cantly lower in both pantoprazole 
groups than in the placebo group, despite placebo recipients 
using signiﬁ  cantly more antacid therapy (p < 0.05 for all 
pantoprazole vs placebo comparisons). No signiﬁ  cant 
differences between pantoprazole 20 mg and 40 mg were 
reported. 
These advantages of on-demand pantoprazole over 
placebo for control of heartburn were conﬁ  rmed for a wider 
range of GERD-associated symptoms in another trial. On-
demand treatment with pantoprazole 20 mg for 6 months 
was effective, compared with placebo, in maintaining control 
of the symptoms of heartburn, acid regurgitation, and pain 
on swallowing in 439 patients with healed Savary-Miller 
grade 0/I GERD. Patients’ perceived average daily symptom 
load was 1.5 and 2.2 for the pantoprazole and placebo 
group, respectively (p < 0.05), and pantoprazole-treated 
patients experienced fewer episodes requiring treatment 
(p < 0.01), and had a lower discontinuation rate due to 
insufﬁ  cient control of symptoms or unsatisfactory treatment. 
Again, antacid usage was signiﬁ  cantly higher in placebo 
recipients than in pantoprazole-treated patients (p < 0.05) 
(Kaspari et al 2005).
In the only identified comparison of on-demand 
administration of active treatments, pantoprazole 20 mg 
significantly reduced the symptom load for heartburn 
compared with esomeprazole 20 mg (1.12 vs 1.32, p = 
0.0115) in 199 patients with Los Angeles classiﬁ  cation grade 
A or B GERD or nonerosive GERD and moderate or severe 
heartburn. Mean intensities of heartburn were signiﬁ  cantly 
lower in the pantoprazole compared with the esomeprazole 
treatment group during the 6 months on-demand treatment 
(1.10 vs 1.33, p = 0.0096) (Figure 1) (Scholten, Bohuschke, 
et al 2005). 
Safety and tolerability
Results of numerous clinical trials indicate that oral 
pantoprazole is safe and well tolerated for short-term 
treatment of GERD and for longer term maintenance therapy 
in patients with healed erosive esophagitis. Oral pantoprazole 
at dosages of up to 40 mg daily was safe and well tolerated 
in studies of 1 to 2 years in duration (Mossner et al 1997; 
Escourrou et al 1999; Van Rensburg et al 1999; Plein et al 
2000; Adamek et al 2001; Metz and Bochenek 2003; Richter 
et al 2004; Labenz et al 2005). Although serum gastrin levels 
tended to increase initially in some, but not all, studies, they 
generally stabilized and were not associated with adverse 
histological findings. Adverse events most commonly 
experienced by patients receiving pantoprazole in these 
long-term trials are those expected in patients receiving PPI 
therapy. Events most frequently include diarrhea, nausea, 
vomiting, headache, dizziness, abdominal pain, infection, 
and raised liver enzymes. These are usually of mild to 
moderate intensity and seldom necessitate discontinuation 
of treatment.
Two longer-term trials have been performed. One 
reported data for treatment with oral pantoprazole for up 
to 3 years. In this study, only 4 of 111 patients had adverse 
events definitely related to pantoprazole. Elevations in 
gastrin were modest and there were no signiﬁ  cant changes 
in gastric endocrine cells (Bardhan et al 2001). The other Therapeutics and Clinical Risk Management 2007:3(2) 237
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is an ongoing 10-year study, in which maintenance therapy 
with pantoprazole 40 mg to 160 mg daily was well tolerated 
in patients with healed peptic ulcers or erosive esophagitis. 
There were no increases in signs associated with an enhanced 
risk of gastric cancer, although fasting serum gastrin levels 
increased slightly after the second year of treatment but 
remained at this level thereafter. Of 134 patients originally 
enrolled in this long-term study, 99 patients were treated with 
pantoprazole for at least 5 years, and 25 had completed 10 
years of treatment (Heinze et al 2003).
The safety proﬁ  le of pantoprazole in elderly patients is 
discussed later in this review. Short-term (up to 8 weeks) 
use of pantoprazole is safe and well tolerated in children and 
adolescents (aged 5 to 16 years) (Madrazo-de la Garza et al 
2003; Tolia et al 2006; Tsou et al 2006).
Impact of GERD on quality of life 
Patients with GERD have signiﬁ  cantly (p < 0.05) poorer 
health-related quality of life than the general population 
(McDougall et al 1996; Revicki et al 1998; Enck et al 1999; 
Kaplan-Machlis et al 1999; Farup et al 2001a; Pare et al 
2003), patients with diabetes or hypertension (Revicki et al 
1998; Enck et al 1999), and patients with severe angina 
pectoris or mild heart failure (Dimenas et al 1993). Although 
there are no relevant differences in health-related quality 
of life between patients with Barrett’s esophagus, erosive 
esophagitis and non-erosive GERD (Kulig et al 2003), 
impairment is proportional to the frequency and severity 
of symptoms, regardless of the presence or absence of 
esophagitis (Dimenas et al 1996; Dent et al 1999; Kaplan-
Machlis et al 1999), is more severe in females and younger 
patients (Holtmann et al 2006b) and is exacerbated by the 
presence of nocturnal symptoms (Farup et al 2001a, 2001b). 
Although the frequency and intensity of acid complaints 
signiﬁ  cantly inﬂ  uence the health-related quality of life of 
patients with GERD (Holtmann et al 2006a), a number of 
other gastrointestinal symptoms, such as upper abdominal/
stomach complaints, lower abdominal/digestive complaints, 
and nausea, also have a major role (Malagelada et al 2006). 
The impact of GERD is most striking on measures of pain, 
mental health, and social function (Revicki et al 1998; Enck 
et al 1999; Farup et al 2001a). The presence of GERD is 
also associated with reduced work productivity for affected 
individuals in the labor force (Henke et al 2000; Sandler 
et al 2002). 
The treatment of GERD improves symptoms and health-
related quality of life outcomes (Wiklund et al 1998; Revicki 
et al 1999; Prasad et al 2003). Control of heartburn strongly 
Figure 1 On-demand therapy with pantoprazole leads to lower heartburn intensity than with esomeprazole in patients with mild GERD.
Note: *Statistically signiﬁ  cant difference; The intensity of symptoms was rated on a 4 point-scale (0: none, 1: mild, 2: moderate, 3: severe).
Abbreviations: ITT, intention to treat population; PP, per protocol population.
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predicts improvement in health-related quality of life during 
the acute treatment of GERD (Pare et al 2003). Although no 
trials of maintenance therapy have reported quality of life 
assessments for pantoprazole, several studies have evaluated 
the effect of short-term pantoprazole on health-related quality 
of life, and results of these studies generally showed the PPI 
to improve health-related quality of life (de-Souza-Cury et al 
2006) and be superior to H2-receptor antagonists (Kaspari 
et al 2001; Pare et al 2003). Health-related quality of life 
improved more rapidly and to a greater extent following 
treatment with pantoprazole 40 mg once daily compared 
with nizatidine 150 mg twice daily in a total of 208 patients 
with GERD characterized by heartburn (with or without 
erosive esophagitis). After 7 days, scores for all assessment 
scales improved more with pantoprazole than nizatidine. 
Patients receiving pantoprazole showed signiﬁ  cantly greater 
improvement in two SF-36 domains, bodily pain (p < 0.01) 
and vitality (p < 0.05), and in the gastrointestinal system 
rating scale (GSRS) reﬂ  ux score (p < 0.01). After 28 days 
of treatment, the changes in scores relative to baseline were 
still greater with pantoprazole than with nizatidine (Pare et al 
2003). Similarly, in comparison with ranitidine, quality of life 
parameters tended to improve more with pantoprazole 20 mg 
once daily than ranitidine 150 mg twice daily according to 
the gastrointestinal quality of life index (GIQLI) and SF-36, 
with a signiﬁ  cant advantage seen for pantoprazole in the SF-
36 vitality score (p < 0.05), in a mixed population of patients 
with nonerosive GERD or endoscopically conﬁ  rmed erosive 
esophagitis. Patients’ assessment of treatment also appeared 
to be more favorable for pantoprazole in this short-term study 
(Kaspari et al 2001). Patient satisfaction with treatment is 
similar with pantoprazole, omeprazole, and lansoprazole (at 
4 and 8 weeks, respectively, patient satisfaction was 79% and 
91% [pantoprazole], 79% and 89% [omeprazole multiple unit 
pellet system (MUPS)] and 76% and 86% [lansoprazole] in 
one study [Mulder et al 2002]).
Recently, a new GERD speciﬁ  c, reliable, sensitive, and 
validated questionnaire for the evaluation of health-related 
quality of life was developed. The GERDyzer™ covers 
10 dimensions of quality of life (general well-being, pain/
discomfort, physical health, energy, daily activities, leisure 
activities, social life, diet/eating/drinking habits, mood and 
sleep) and has demonstrated very high internal consistency, 
good test-retest reliability, responsiveness and construct 
validity in patients treated with pantoprazole (Holtmann et al 
2005). Using this questionnaire in conjunction with the 
ReQuest™- GI (Stanghellini V et al 2005), all dimensions 
of treatment satisfaction were shown to increase during 4 weeks 
of treatment with pantoprazole, with good treatment satisfaction 
reported after the ﬁ  rst week of therapy (DeVault et al. 2006).
Treating patients with GERD is about 2-fold more costly 
than treating those without GERD (Bloom et al 2001). 
However, PPIs have the lowest total cost per patient of 
the available pharmacological treatments, when total costs 
(deﬁ  ned as the costs of diagnosis and initial treatment, and the 
costs associated with treatment success, treatment failure and 
remission) are calculated, despite having higher acquisition 
costs than other acid suppressive agents (Holzer et al 1998). 
Scant pharmacoeconomic data speciﬁ  c for pantoprazole 
are available. The only study identiﬁ  ed, a modelling study 
in the Netherlands, showed that pantoprazole may have a 
more favorable pharmacoeconomic proﬁ  le than omeprazole. 
Assumptions were based on available documentation 
concerning the effectiveness and costs of omeprazole and 
pantoprazole and ﬁ  ndings are only valid if the substitution 
of omeprazole by pantoprazole can be achieved without loss 
of efﬁ  cacy or tolerability (van Hout et al 2003).
Special considerations in the elderly
GERD appears to be more common and more severe in 
the elderly than in younger individuals; in fact age is an 
important risk factor for the development of severe forms 
of GERD (El-Serag and Sonnenberg 1997; Johnson and 
Fennerty 2004). In the primary care setting in the US, as 
many as 20% of older patients report acid reﬂ  ux (Mold et al 
1991), and in a Japanese study, the prevalence of erosive 
esophagitis in patients aged >70 years was more than triple 
the prevalence in patients younger than 39 years (Maekawa 
et al 1998). In common with the general population, the 
intensity and frequency of heartburn and other symptoms 
of GERD are poor predictors of the presence or severity of 
esophageal manifestations. In addition, older patients are less 
likely to experience severe heartburn than younger patients 
(Johnson and Fennerty 2004) and the majority (over 75%) 
do not experience acid regurgitation as an initial symptom 
(Räihä et al 1991; Pilotto and Franceschi 2003). More 
frequently, elderly patients with GERD report symptoms 
such as dysphagia, vomiting and respiratory difﬁ  culties, 
anorexia, weight loss, and anemia-melena (Pilotto and 
Franceschi 2003). Because of this different symptom proﬁ  le 
of GERD in the elderly, the disease, particularly in milder 
form, may remain undiagnosed for a considerable period of 
time (Maekawa et al 1998) resulting in hospital admittance 
for more severe disease (Zimmerman et al 1997).Therapeutics and Clinical Risk Management 2007:3(2) 239
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Elderly patients require endoscopy as the initial diagnostic 
test for GERD, irrespective of the severity or duration of 
their symptoms—endoscopy is even indicated in elderly 
patients without current typical symptoms, but with a past 
history of GERD (Richter 2000). However, endoscopy can 
be associated with the risk of complications, particularly in 
elderly patients with heart or pulmonary disease, and so use 
of well validated symptom assessment tools may increasingly 
have a role in the diagnosis and long term management of 
GERD in elderly patients. Based on their safety proﬁ  les and 
success in the general patient population, PPIs as a class 
are considered ﬁ  rst-line treatment for GERD and erosive 
esophagitis in the elderly (Bacak et al 2006).
Results of a retrospective analysis, based on combined 
data from two prospective, double-blind, randomized trials 
in patients with Hetzel-Dent grade ≥2 erosive esophagitis, 
show that healing rates with pantoprazole 40 mg are similar in 
elderly patients and in younger patients. At 8 weeks, healing 
rates were 86% in the 44 patients aged ≥65 years and 83% 
in the 210 patients aged <65 years. Pantoprazole was more 
effective than a combined placebo/nizatidine treatment group 
(p < 0.001) (DeVault et al 2003).
Results of a prospective study have conﬁ  rmed the efﬁ  cacy 
of oral pantoprazole in 164 patients aged ≥65 years with 
Savary-Miller grade I-III GERD. Patients initially received 
pantoprazole 40 mg daily for 8 weeks and 81% achieved 
documented healing of erosive esophagitis. All healed 
patients subsequently received maintenance therapy with 
pantoprazole 20 mg daily; 82% remained in remission at 6 
months. Continued therapy with pantoprazole 20 mg daily for 
a further 6 months maintained a remission rate of 80% at 1 
year, whereas switching to placebo for the last 6 months of the 
trial resulted in a remission rate of 30% (Pilotto et al 2003). 
These results show that pantoprazole is highly effective 
for healing and reducing the relapse of erosive esophagitis, 
and that discontinuing active treatment after 6 months is 
associated with a signiﬁ  cant increase in the risk of relapse. 
In this study, the most commonly reported adverse events 
were glossitis, headache, and diarrhea. These ﬁ  ndings are in 
agreement with data for nonelderly populations.
When treating elderly patients with GERD, concomitant 
medications should be considered for two main reasons. 
Firstly, it is known that a number of medications commonly 
prescribed for elderly patients may promote gastroesophageal 
reﬂ  ux and, secondly, drug interactions may be of particular 
importance in these patients as they are frequently receiving 
multiple drug therapies (Pilotto et al 2005; Gorard 2006; 
Steinman et al 2006). When considering treatment with PPIs, 
it is important to note that interactions caused by changes in 
gastric pH are a group-speciﬁ  c effect, but each PPI differs in 
its propensity to interact with other drugs and the extent to 
which its interaction proﬁ  le has been deﬁ  ned. The interaction 
proﬁ  les of omeprazole and pantoprazole have been studied 
most extensively: omeprazole carries a considerable potential 
for drug interactions, whereas pantoprazole appears to have 
lower potential for interactions with other medications. 
The interaction proﬁ  les of esomeprazole, lansoprazole, and 
rabeprazole have been less extensively investigated, but 
evidence suggests that lansoprazole and rabeprazole have 
weaker potentials for interactions than omeprazole, and 
esomeprazole has a propensity for drug interactions similar to 
that of omeprazole. (Blume et al 2006). This pharmacokinetic 
proﬁ  le suggests that pantoprazole is well suited for use in 
elderly patients who as a group frequently present with 
comorbidities and receive multiple therapies.
Conclusion 
The optimal treatment of GERD is vital for a number of 
reasons. GERD is a chronic, relapsing disease that can progress 
to major complications; affected patients have signiﬁ  cantly 
poorer health-related quality of life than the general population, 
with impairment being proportional to the frequency and 
severity of symptoms; and as GERD requires continued 
therapy to prevent relapse and complications, most patients 
with erosive esophagitis require long-term acid suppressive 
treatment. Thus GERD results in a signiﬁ  cant cost burden.
The effective treatment of GERD provides symptom 
resolution and high rates of remission in erosive esophagitis, 
lowers the incidence of GERD complications, improves 
health-related quality of life and reduces the cost of this 
disease. PPIs are accepted as the most effective treatment for 
GERD and are the mainstay of initial GERD management, 
providing more rapid symptom control and better healing 
of erosive esophagitis than H2-receptor antagonists and 
antacids. PPIs are also the preferred agents for maintenance 
therapy in patients with healed erosive esophagitis (Lauritsen 
et al 2003). As few differences in safety or efﬁ  cacy have 
been reported between the available PPIs, the decision to 
select one PPI over another is most likely to be based on 
the agents’ acquisition costs, formulations, Food and Drug 
Administration-labeled indications, and overall safety 
proﬁ  les (Welage and Berardi 2000).
The data reviewed here show that oral pantoprazole is 
a safe, well tolerated and effective initial and maintenance Therapeutics and Clinical Risk Management 2007:3(2) 240
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treatment for patients with nonerosive GERD or erosive 
esophagitis. Oral pantoprazole has greater efﬁ  cacy than that 
of H2-receptor antagonists and generally has similar efﬁ  cacy 
to other PPIs for the initial and maintenance treatment of 
GERD. In addition, oral pantoprazole has been shown 
to improve the quality of life of patients with GERD 
and is associated with high levels of patient satisfaction 
with therapy. GERD appears to be more common and 
more severe in the elderly. Furthermore, as elderly are 
taking multiple medications at the same time, or drugs with 
a narrow therapeutic window, drug interactions may be of 
particular importance in those patients. Pantoprazole has also 
shown to be an effective and safe treatment for this at-risk 
population.
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